Additionally, epigallocatechin-3-gallate changes fatty acid uptake, fat production, and the expression of metabolism related regulatory genes in adipose tissue to reduce the occurrence of obesity, and the increase of GLP-1 and PYY levels might be involved in this regulatory process [173]. This evidence concerns the gene PYY and obesity disorder.